Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI – Get Free Report) hit a new 52-week high during trading on Tuesday . The stock traded as high as $18.11 and last traded at $17.71, with a volume of 2460685 shares. The stock had previously closed at $17.21.
Wall Street Analyst Weigh In
A number of research analysts recently issued reports on the company. Wall Street Zen raised Trevi Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday. D. Boral Capital restated a “buy” rating and issued a $19.00 price objective on shares of Trevi Therapeutics in a research report on Friday, April 17th. Oppenheimer reaffirmed an “outperform” rating on shares of Trevi Therapeutics in a research note on Monday, March 9th. JonesTrading reduced their target price on shares of Trevi Therapeutics from $25.00 to $24.00 and set a “buy” rating on the stock in a research report on Thursday, March 19th. Finally, Needham & Company LLC reissued a “buy” rating and set a $23.00 price target on shares of Trevi Therapeutics in a research note on Wednesday, May 20th. Two research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Buy” and an average target price of $22.90.
View Our Latest Report on TRVI
Trevi Therapeutics Stock Up 2.9%
Trevi Therapeutics (NASDAQ:TRVI – Get Free Report) last posted its quarterly earnings results on Tuesday, May 5th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by ($0.02). As a group, sell-side analysts expect that Trevi Therapeutics, Inc. will post -0.47 EPS for the current fiscal year.
Institutional Inflows and Outflows
Hedge funds have recently modified their holdings of the business. Pivotal bioVenture Partners Investment Advisor LLC increased its holdings in Trevi Therapeutics by 9.7% in the third quarter. Pivotal bioVenture Partners Investment Advisor LLC now owns 1,256,782 shares of the company’s stock valued at $11,500,000 after purchasing an additional 110,672 shares during the last quarter. Nan Fung Trinity HK Ltd. boosted its holdings in Trevi Therapeutics by 924.2% during the fourth quarter. Nan Fung Trinity HK Ltd. now owns 917,450 shares of the company’s stock worth $11,486,000 after buying an additional 827,875 shares during the last quarter. F m Investments LLC acquired a new position in shares of Trevi Therapeutics during the 4th quarter worth about $3,023,000. Pictet Asset Management Holding SA increased its stake in shares of Trevi Therapeutics by 13,507.0% in the 4th quarter. Pictet Asset Management Holding SA now owns 1,532,013 shares of the company’s stock valued at $19,181,000 after acquiring an additional 1,520,754 shares during the last quarter. Finally, Comerica Bank increased its stake in shares of Trevi Therapeutics by 19,481.8% in the 4th quarter. Comerica Bank now owns 83,027 shares of the company’s stock valued at $1,039,000 after acquiring an additional 82,603 shares during the last quarter. Institutional investors own 95.76% of the company’s stock.
Trevi Therapeutics Company Profile
Trevi Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of novel non-opioid therapies for the management of chronic and acute pain. The company leverages proprietary drug delivery platforms and targeted molecular approaches to address high unmet needs in cancer-related pain, chemotherapy-induced neuropathy and other severe pain conditions.
Its lead product candidate is a proprietary formulation of tetrodotoxin (TTX), a sodium-channel blocking agent being evaluated in early-stage clinical trials for moderate-to-severe pain associated with advanced cancer and peripheral neuropathy.
Featured Articles
- Five stocks we like better than Trevi Therapeutics
- Buy CrowdStrike Before the Stock Split? Here’s the Case
- Investors Are Buying Into Sweetgreen Again—Should They?
- Burlington Is Winning Over Shoppers But Investors Need Patience
- USA Today’s Digital Revival Is Gaining Steam, But With Plenty of Risk
Receive News & Ratings for Trevi Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevi Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
